LIXTE Biotechnology Holdings, Inc. Regains Compliance with Nasdaq Continued Listing Requirements
23 Giugno 2023 - 2:30PM
LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT) (“LIXTE” or the
“Company”) announced today that it has received confirmation from
The Nasdaq Stock Market LLC (“Nasdaq”) that it has regained
compliance with the minimum bid price requirement of $1.00 per
share under Nasdaq Listing Rule 5550(a)(2) and currently meets all
other applicable criteria for continued listing.
On June 24, 2022, Nasdaq notified LIXTE that its
common stock failed to maintain a minimum bid price of $1.00 per
share over the previous 30 consecutive trading days as required by
the Listing Rules of Nasdaq. In order to address this issue, the
Company effected a 1-for-10 reverse stock split of its issued and
outstanding shares of common stock on Friday, June 2, 2023, as a
result of which the Company’s common stock commenced trading on a
post-split basis beginning on Monday, June 5, 2023.
About LIXTE Biotechnology Holdings,
Inc.
LIXTE Biotechnology Holdings, Inc. is a
clinical-stage pharmaceutical company focused on new targets for
cancer drug development and developing and commercializing cancer
therapies. LIXTE has achieved a breakthrough demonstrating that its
first-in-class lead clinical PP2A inhibitor, LB-100, is
well-tolerated in cancer patients at doses associated with
anti-cancer activity. Based on extensive published preclinical data
(see www.lixte.com), LB-100 has the potential to significantly
improve outcomes for patients undergoing various chemotherapies or
immunotherapies. LIXTE's new approach has no known competitors and
is covered by a comprehensive patent portfolio. Initial
proof-of-concept clinical trials are in progress.
For more information about
LIXTE, contact:
info@lixte.comGeneral Phone: (631) 830-7092; Investor Phone:
(888) 289-5533
or
PondelWilkinson Inc. Investor
Relationspwinvestor@pondel.comRoger Pondel: (310) 279-5965; Laurie
Berman: (310) 279-5962
Grafico Azioni Lixte Biotechnology (NASDAQ:LIXT)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Lixte Biotechnology (NASDAQ:LIXT)
Storico
Da Lug 2023 a Lug 2024